

Pharmaceutical company request for oral testimony at the May 15,2020
Idaho Medicaid Pharmacy & Therapeutics Committee meeting.

Submission # _02

Date request was received: 04/20/2020

Drug: Invokana

Therapeutic Drug Class: Hypoglycemics SGLT2

Pharmaceutical Company: Janssen

This request for oral testimony has been reviewed.

Denied for oral testimony.

From: Trivedi, Neeti [COBIUS] <NTrivedi@its.jnj.com>
Sent: Monday, April 20, 2020 1:06 PM
To: Eide, Tamara J. <Tamara.Eide@dhw.idaho.gov>
Subject: JANSEN - INVOKANA & SYMTUZA - Idaho Medicaid [External Email]

ATTN: **Tami Eide**
3232 Elder Street
Boise, ID 83705

Dear Members of the State of Idaho Pharmacy and Therapeutics (P&T) Committee,

Please see the attached summary of clinical information provided for INVOKANA® (canagliflozin) and SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) marketed by Janssen Pharmaceuticals, Inc., and submitted in preparation for the upcoming **Idaho Medicaid P&T Committee Meeting** on behalf of Stephanie Yamamoto, PharmD, BCPS, Field Director West, Real World Value & Evidence Field.

The enclosed information has been supplied to you in response to your unsolicited request and is not intended as an endorsement of any usage not contained in the prescribing information. For complete information, please refer to the full Prescribing Information below, including the following sections: BOXED WARNING(S), INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS. If you require further information, please feel free to contact me directly Monday through Friday, 9:00 a.m. to 5:00 p.m. EST.

Thank you,
Neeti

Neeti Trivedi, PharmD, MBA
Associate Director, Payer & Health Systems, Medical Information
Janssen Scientific Affairs, LLC
1125 Trenton-Harbourton Road, Titusville, NJ 08560
Phone: 609.730.6588
Email: ntrivedi@its.jnj.com
Case #: 01728081

